A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Hoffmann-La Roche
National Cancer Institute (NCI)
Instituto do Cancer do Estado de São Paulo
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Case Comprehensive Cancer Center